度伐利尤单抗联合化疗与SABR治疗寡转移性非小细胞肺癌:多中心2期研究
这项多中心单臂2期研究评估度伐利尤单抗联合铂双药化疗及SABR治疗初治寡转移IV期驱动基因阴性非小细胞肺癌的疗效与安全性,主要终点为研究者评估的PFS。35例入组,中位随访24.7个月,全分析集中位PFS 10.4个月,2年PFS率38.5%、OS率67.7%;接受SABR者中位PFS 24.3个月优于未接受SABR者的3.1个月。
要点
- 全分析集中位PFS 10.4个月,2年PFS率38.5%,2年OS率67.7%。
- ≥3级治疗相关不良事件发生率57.1%,免疫相关不良事件25.7%。
核心结论
- 在寡转移性NSCLC中,度伐利尤单抗联合化疗与SABR有效且可耐受。
- 既往系统治疗后未进展并接受SABR的患者可能获得最佳结局。
研究设计与样本
- 多中心、2期、单臂研究,评估度伐利尤单抗联合化疗与SABR用于既往未接受系统治疗的寡转移IV期NSCLC。
- 主要终点为研究者根据RECIST 1.1评估的PFS,共入组35例患者。
主要发现
- 全分析集(n=35)中位PFS 10.4个月(95%CI 4.4-26.1),2年PFS率38.5%(95%CI 21.9-54.8),2年OS率67.7%(95%CI 49.0-80.7)。
- 符合方案集(n=32)中位PFS 14.6个月(95%CI 4.7-26.1),2年PFS率42.4%(95%CI 24.3-59.4),2年OS率70.8%(95%CI 51.2-83.8)。
- ≥3级治疗相关不良事件发生率为57.1%(20/35),免疫相关不良事件为25.7%(9/35)。
临床怎么用
- 对初治寡转移性驱动基因阴性NSCLC,可考虑度伐利尤单抗联合铂双药化疗并联合SABR。
- 治疗期间需关注≥3级治疗相关不良事件及免疫相关不良事件。
局限性
- 单臂设计,无随机对照,样本量较小(35例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immunotherapy plus chemotherapy is the standard of care for driver-gene negative metastatic non-small cell lung cancer (NSCLC). Synchronous oligometastatic disease has a better prognosis than extensive metastasis, and the addition of stereotactic ablation body radiotherapy (SABR) results in improved efficacy. However, whether the combination of SABR with immunotherapy and platinum-doublet chemotherapy will lead to long-term disease control or even cure for patients remains unclear. METHODS AND MATERIALS: This was a multicenter, phase 2, single-arm study to evaluate the efficacy and safety of durvalumab in combination with chemotherapy and SABR for oligometastatic stage IV NSCLC without previous systemic therapy. The primary endpoint was investigator-assessed progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: Thirty-five patients were enrolled in the study. Twenty-eight (80%) patients received radiation therapy, including 23 (65.7%) who received SABR. The median follow-up time was 24.7 months (95% CI, 21.6-27.5). In the full analysis set (n = 35), the median PFS (mPFS) was 10.4 months (95% CI, 4.4-26.1), and the 2-year PFS rate and overall survival (OS) rate were 38.5% (95% CI, 21.9-54.8) and 67.7% (95% CI, 49.0-80.7), respectively. In the per-protocol set (n = 32), mPFS was 14.6 months (95% CI, 4.7-26.1), and the 2-year PFS rate and OS rate were 42.4% (95% CI, 24.3-59.4) and 70.8% (95% CI, 51.2-83.8), respectively. The subgroup analysis showed that the mPFS was 24.3 months (95% CI, 7.6-NE) with SABR versus 3.1 months (95% CI, 1.4-4.7) without SABR (hazard ratio [HR], 0.2; 95% CI, 0.09-0.5; P < .001). Grade 3 or higher treatment-related adverse events (TRAEs) and immune-mediated adverse events (imAEs) were reported in 57.1% (20/35) and 25.7% (9/35) of patients, respectively. CONCLUSIONS: In oligometastatic NSCLC, the combination of durvalumab, chemotherapy, and SABR was effective and tolerable. Patients who did not experience disease progression after prior systemic therapy and received SABR might have optimal outcomes.
引用
- Li Q, Ma H, Zheng R, et al. Durvalumab Combined With Chemotherapy and SABR Therapy in Patients With Oligometastatic Non-small Cell Lung Cancer: A Multicenter Phase 2 Study. Int J Radiat Oncol Biol Phys. 2025. PMID: 41005623. doi:10.1016/j.ijrobp.2025.09.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。